Matus R E, Leifer C E
Vet Clin North Am Small Anim Pract. 1985 Jul;15(4):741-53. doi: 10.1016/s0195-5616(85)50033-9.
Multiple myeloma and macroglobulinemia are the most common immunoglobulin-producing neoplasms seen in the dog. Treatment with the alkylating agents in combination with prednisone may significantly prolong survival. Supportive management of associated complications is imperative to ensure that the individual case receives optimal care. The use of clinical staging seems to be of value in establishing prognosis; however, response to therapy may be more significant, for many dogs present with advanced disease. In the high-risk patient, one should consider using investigational combination drug protocols which are available at a referral center. Although a "cure" is unlikely, the prospect of the animal having a fairly normal, healthy life for an extended period of time (over a year in the majority of cases) should encourage veterinarians to recommend evaluation for treatment in dogs with multiple myeloma and macroglobulinemia.
多发性骨髓瘤和巨球蛋白血症是犬类中最常见的产生免疫球蛋白的肿瘤。使用烷化剂联合泼尼松进行治疗可显著延长生存期。对相关并发症进行支持性管理对于确保个体病例获得最佳护理至关重要。临床分期的应用似乎对判断预后有价值；然而，由于许多犬只就诊时已处于晚期疾病阶段，治疗反应可能更为重要。对于高危患者，应考虑使用转诊中心提供的试验性联合用药方案。虽然不太可能“治愈”，但动物在较长一段时间内（大多数情况下超过一年）拥有相当正常、健康生活的前景，应促使兽医建议对患有多发性骨髓瘤和巨球蛋白血症的犬只进行治疗评估。
